Latest results on Oncofid®P-B, at the American Urological Association’s 2019 Annual Meeting

Fidia farmaceutici today announced the positive preliminary results from an open-label, single-arm, multicenter clinical trial evaluating safety, tolerability and efficacy of Oncofid®P-B, an innovative Paclitaxel-Hyaluronic Acid conjugate, in patients with carcinoma in situ (CIS) of the bladder, unresponsive or intolerant to BCG (Bacillus Calmette-Guérin) and unwilling or unfit for cystectomy.

Dr. Rodolfo Hurle, Principal Investigator at Humanitas Research Hospital in Milan (Italy) was invited as a podium speaker on Friday, May 3 at 4:00 PM (Chicago Local Time) and explained the results and conclusions of the trial.

Good efficacy and excellent tolerability

Oncofid®P-B showed excellent tolerability for a prolonged treatment schedule and good efficacy, with 72.2% complete response in patients who completed the 12-week induction phase, followed by 12 monthly instillations (maintenance),

A pharmacological alternative to cystectomy

CIS of the bladder is still an unmet medical need and the excellent safety profile and positive preliminary efficacy results obtained with Oncofid®P-B when administered according to a prolonged treatment schedule support the further clinical development of this innovative drug - said Dr. Hurle – providing a potential pharmacological alternative to cystectomy for these high-risk patients”.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine